Only HER2 Breast Cancer benefits from Adrymycian
 

Results from two studies presented Thursday at the 30th annual San Antonio Breast Cancer Symposium now reveal that only women with HER2 positive breast cancer -- a subset which accounts for only about 8 percent of women with breast cancer worldwide -- will benefit significantly from standard anthracycline-based chemotherapy.

Read entire article:

http://www.abcnews.go.com/Health/OnC...4001402&page=1